Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 Chemoradiotherapy vs Radiotherapy in Elderly Esophageal Cancer
NCT02979691Phase 3Completed
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Oct 2016
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tegafur in esophageal cancer and esophagogastric junction cancer (2 arms), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Overall Survival at 1 year. Started Oct 2016; status: completed.
02
Drugs
tegafur
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on NCT02979691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02979691.